Developing Oral Biologics to Treat Disease at its Origin
~ 75 percent of the entire immune system is located in the GI tract.
With privileged access to the immune-cell rich GI environment, AMT’s lead product candidates are designed to intercept disease biology at critical sites by directly targeting signaling axes within the GI tract.
AMT has a robust pipeline of oral biologic product opportunities engineered to gain privileged access to the immune system and the hepatic portal system by crossing intestinal epithelial barriers. This privileged access provides the opportunity to address disease at its point of origin and creates the potential to achieve greater efficacy and tolerability than seen with parenterally administered therapeutics, particularly in the areas of immunology and inflammation, liver and metabolic diseases.
|Program||Therapeutic Area||Preclinical||Phase 1||Phase 2|
|AMT-101||Oral GI-selective immunomodulator (IL-10 fusion)||Immunology & Inflammation||
|AMT-126||Oral GI-selective barrier function defect correction (IL-22 fusion)||Immunology & Inflammation, Liver, Metabolic Diseases||
|AMT-115||Oral GI-selective TNFα inhibitor fusion||Immunology & Inflammation||
|AMT-221||Oral incretin peptide||Diabetes & Obesity, Liver||
|AMT-205||Oral endocrine protein||Metabolic Diseases||
Oral GI-selective immunomodulator (IL-10 fusion)
|Immunology & Inflammation||Phase 1/2|
Oral GI-selective barrier function defect correction (IL-22 fusion)
|Immunology & Inflammation, Liver, Metabolic Diseases||Preclinical|
Oral GI-selective TNFa inhibitor fusion
|Immunology & Inflammation||Preclinical|
Oral incretin peptide
|Diabetes & Obesity, Liver||Preclinical|
Oral endocrine protein